GlassScriptPhysician profile
John Warren Mcbroom
NPI 1568439768
$186,593.96
in general payments reported to CMS, 2019-2025
23 companies · $24K in 2025
The $24K reported for 2025 was more than what 94% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $7,763 · 2021: $13K · 2022: $56K · 2023: $7,725 · 2024: $35K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Consulting Fee: $11K · Travel and Lodging: $7,563 · Food and Beverage: $1,735 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,671.00 |
| Consulting Fee | $10,678.00 |
| Travel and Lodging | $7,562.63 |
| Food and Beverage | $1,734.77 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $91,503.28 | 2019-2025 | Zejula, Jemperli |
| Abbvie INC. | $45,061.75 | 2019-2025 | |
| Tesaro, INC. | $26,089.80 | 2019 | |
| Clovis Oncology, INC. | $17,700.56 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $3,565.04 | 2019-2020 | |
| Medical Device Business Services, INC. | $1,249.61 | 2024 | |
| Pfizer INC. | $275.54 | 2024-2025 | |
| Eisai INC. | $249.28 | 2019-2025 | |
| Amgen INC. | $173.04 | 2019-2020 | |
| Caris Mpi, INC. | $115.64 | 2025 | Mi Cancer Seek |
| Ethicon US, LLC | $111.48 | 2024-2025 | Stratafix, Vistaseal, Echelon Circular |
| Seagen INC. | $99.99 | 2023 | |
| Myriad Genetic Laboratories, INC. | $97.45 | 2022 | |
| Merck Sharp & Dohme LLC | $96.99 | 2019 | |
| Genentech USA, INC. | $56.77 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verastem, INC. | $26.06 | 2025 | Avmapki Fakzynja Co-Pack |
| Aspira Women'S Health INC | $23.69 | 2024 | Ova1 |
| Fennec Pharmaceuticals, INC. | $20.65 | 2025 | Fyarro |
| Conmed Corporation | $16.91 | 2025 | Abc Handpieces |
| Kyowa Kirin, INC. | $16.71 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.05 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $15.18 | 2019 | |
| Coopersurgical, INC. | $12.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mcbroom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.